News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Pharmaceuticals Extends its Platform of Novel Anti-Cancer Technologies

Posted on: 09/01/2004

Peregrine Pharmaceuticals Extends its Platform of Novel Anti-Cancer Technologies

Press Release Source: Peregrine Pharmaceuticals, Inc.
Wednesday September 1, 2:02 pm ET
Announces Issuance of U.S. Patent No. 6,783,760 for Treating Cancer using Antibodies in Combination with Standard Cancer Therapy

TUSTIN, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News) announced today the grant of a new patent for the development of novel compounds that deliver cancer drugs directly to tumor blood vessels to enhance standard anti-cancer therapy. Compounds covered by the new patent include methods for treating tumors using antibodies and proteins that bind to tumor blood vessels combined with standard cancer therapies including radiotherapy and chemotherapy. These novel compounds, which include Anti-Phospholipid Therapy (APT) agents such as Tarvacin(TM), bind specifically to aminophospholipids and may be used to enhance anti-tumor effects of standard anti-cancer therapies without harming normal, healthy cells surrounding the tumor.

"Issuance of this new patent extends Peregrine's already strong intellectual property position, and also provides important clinical applications for our Vascular Targeting Agent (VTA) program," said Steven King, Peregrine's president and CEO. "This new patent is particularly important since we believe that VTAs will be advantageously used in combination with standard anti-cancer therapies including surgery, radiotherapy and chemotherapy."

Aminophospholipids, which include phosphatidylserine (PS) and phosphatidylethanolamine (PE), are the foundation of Anti-Phospholipid Therapy (APT). They are targets for anti-cancer therapies because they are arranged differently on cells in tumor blood vessels than are lipids on normal, healthy cells. In normal cells, aminophospholipids are found on the inside of the cellular membrane -- the outermost layer of the cell. Studies have shown, however, that these lipids are found on the outside of the cellular membrane in the tumor vasculature. By combining the APT agent with standard cancer therapies, the novel compounds are capable of directly attacking the cancer tumor through the tumor blood vessels -- a platform technology referred to a Vascular Targeting Agents.

Early Experience with APT Antibodies

Peregrine already has several APT agents under development. Data from pre-clinical research studies show that these agents are able to specifically bind to cells on the outside of tumor vessels. In addition, pre-clinical results indicate potential single-agent activity with APT therapies as well. In studies, one of Peregrine's APT antibodies was shown to significantly inhibit tumor growth in a variety of rodent tumor models, in some instances, up to 50 percent.

Further, data collected by researchers from the University of Texas Southwestern Medical Center at Dallas show that APT antibodies significantly enhance the effectiveness of chemotherapy. In one pre-clinical study, breast cancer tumors were treated with a combination of an APT antibody and the widely used breast cancer chemotherapy treatment, docetaxel. The combination therapy resulted in a 93 percent inhibition of human breast cancer growth compared to 68 percent and 60 percent in groups treated with docetaxel or the APT antibody alone. In addition, therapy with the APT antibody alone was very well tolerated and did not enhance toxicities seen with docetaxel alone.

Peregrine is also developing APT compounds for use as anti-viral agents as aminophospholipids are also found on the outside of viruses.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals is a biopharmaceutical company primarily engaged in the research, development, manufacture and commercialization of cancer therapeutics and diagnostics through a series of proprietary platform technologies. The company is primarily focused on discovering and developing products that affect blood vessels and blood flow in cancer and other diseases. Peregrine's vascular research programs fall under several different proprietary platforms including Anti-Phospholipid Therapy (APT), Vascular Targeting Agents (VTAs), Anti-Angiogenesis and Vasopermeation Enhancement Agents (VEAs). The company expects to enter its first APT compound, Tarvacin(TM) into clinical trials for cancer therapy during calendar year 2004.

Peregrine's most clinically advanced therapeutic program is known as Tumor Necrosis Therapy (TNT) and targets dead or dying tumor cells that are common to the majority of different tumor types. Peregrine's TNT therapy Cotara® is approved in Japan for the treatment of lung cancer and the company will soon begin a Phase II clinical trial in the United States to assess the safety and efficacy of Cotara® for the treatment of brain cancer. Cotara® is also approved in China for the treatment of lung cancer under a licensing arrangement. In addition, enrollment was recently completed in a Phase I clinical trial for the treatment of colorectal carcinoma at Stanford University Medical Center using Cotara®. Data collected from the Phase I study will be used to evaluating a possible Phase II clinical trial in the United States to assess the safety and efficacy of Cotara® for the treatment of other solid tumors, such as lung cancer. In addition, the company received protocol approval from the U.S. Food and Drug Administration ("FDA") to initiate a registration clinical study in February 2003 for the treatment of brain cancer using Cotara®. The company is currently seeking a development or funding partner to move the brain cancer program forward.

The company's wholly owned subsidiary, Avid Bioservices, Inc. (, is a manufacturing facility for monoclonal antibodies and recombinant proteins Avid produces clinical trial materials to support Phase I through Phase III clinical trials for biotechnology companies including Peregrine.

Copies of Peregrine press releases, SEC filings, current price quotes and other valuable information for investors may be found at

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information presented herein, matters discussed in this release contain certain forward- looking statements. The inclusion of forward-looking statements should not be regarded as a representation by us or any other person that the objectives or plans will be achieved. The words "may," "should," "plans," "believe," "anticipate," "estimate," "expect," their opposites and similar expressions are intended to identify forward-looking statements. We caution readers that such statements are not guarantees of future performance or events and are subject to a number of factors that may tend to influence the accuracy of the statements, including but not limited to, risk factors discussed in Peregrine's report on Form 10-K for the year ended April 30, 2004 and subsequent quarterly reports on Form 10-Q. Peregrine disclaims any obligation and does not undertake to update or revise the forward-looking statements discussed in this press release.
Peregrine Investor Relations
Frank Hawkins and Julie Marshall
Hawk Associates, Inc.
(800) 987-8256 or

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557